A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

NCT07748208 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Diabetes Type II

Interventions

DRUG: Inavolisib
DRUG: Fulvestrant
DRUG: Palbociclib

Sponsor

Hoffmann-La Roche